Erenna® Total GLP-1(Plate-based) Immunoassay Kit (Cat# 03-0066-xx)

Introduction

The Erenna® Total GLP-1 Immunoassay uses a quantitative fluorescent sandwich immunoassay technique to measure Total GLP-1 (7-36 amide + 9-36 amide) in plasma samples. A capture antibody specific for the C-terminus of x-36 amide GLP-1 has been pre-coated to a 384-well microplate. The user pipettes standards and samples into microplate wells and incubates the plate. During incubation, the Total GLP-1 present in the sample binds to the solid phase capture antibody. After the first incubation, the assay plate is washed to remove unbound molecules and detection antibody is added into microplate wells. This detection antibody recognizes and binds to a mid molecular epitope of Total GLP-1 that has been captured onto the solid phase. After washing, elution buffer is added and incubated to dissociate the bound protein sandwiches from the plate surface. A neutralization buffer is then added to the eluted antibodies. The fluorescent antibodies are now neutralized and free-floating in the wells. The plate is loaded into the Erenna System and the fluorescent molecules are counted. The number of fluorescently labeled detection antibodies counted is directly proportional to the amount of Total GLP-1 that was present in the sample when captured. The amount of Total GLP-1 in unknown samples is interpolated off of the standard curve.

Assay Performance

TABLE 1. Analytical sensitivity of the Erenna® Total GLP-1(Plate-based) Immunoassay Kit¹
Lower Limit of Detection	1 pg/mL
Lower Limit of Quantification²	8 pg/mL
Upper Limit of Quantification	1000 pg/mL
Low-end CV% Range	7 - 15%
Low-end CV% Average	10%
Recommended Sample Volume	10 μL
Minimum Sample Volume Required³	5 μL

¹ See product insert for updated values
² LLoQ = 20% CV and ± 20% recovery
³ based upon median [GLP-1, total (Plate-based)] in a healthy reference

FIGURE 1. [Total GLP-1] from 9 healthy EDTA plasma donors, with median and interquartile range.

FIGURE 2. Erenna® Total GLP-1 (Plate-based) Immunoassay Kit low-end standard curve signal (left) and curve fi t (right).

Representative data shown for demonstration purposes only. Individual results may vary depending upon samples tested and protocol used.

Biology and Disease

Glucagon-Like Peptide-1 (GLP-1) is a member of the incretin family of hormones, which are released by the gut into the bloodstream in response to food. Post-translational cleavage of the peptide produces active GLP-1, which is then rapidly degraded by protease dipeptidyl peptidase-4 (DPP-4). When blood glucose level is high, active GLP-1 enhances insulin secretion and also suppresses the release of glucagon. In addition, GLP-1 stimulates the brain to trigger feelings of satiety and regulates the rate of gastric emptying. Compared to healthy controls, some patients with type-2 diabetes show a modest decrease in GLP-1 release. Therapeutic GLP-1 analogs such as exenatide, or DPP inhibitors like sitagliptin, are promising strategies for treating type-2 diabetes.

TABLE 2. Additional UniProtKB/Swiss-Prot Information*
Protein Name:
UniProtKB/Swiss-Prot ID:
Protein-protein interaction database:
Alternative Names:
Gene Names:
Synonym Gene Names:
Function:
Biological Processes:
Molecular Function:

* Source Info from www.uniprot.org.

Related Products


Analyte	Description	Catalog #
GLP-1, active (Plate-based)	Erenna® Active GLP-1 (Plate-based) Immunoassay Kit	03-0065-xx
GLP-1, total (MP-based)	Erenna® Total GLP-1(MP-based) Immunoassay Kit	03-0025-xx
Mouse, (Plate-based) Insulin	Erenna® Mouse (Plate-based) Insulin Immunoassay Kit	03-0006-xx